FDA approves Opdivo (nivolumab) with chemotherapy as neoadjuvant treatment for certain adults with resectable non-small cell lung cancer, Bristol Myers Squibb says.
- Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
- Bristol-Myers Squibb Co. fell 0.2% in postmarket trading to $69.25 as of 5:45 p.m. New York time
- The average 12-month price target of $72.90 is 5.3% above the current price
- 15 buys, 9 holds, 0 sells
To view the source of this information, click
To contact the reporter on this story:
To contact the ...